Page 1

Hong Kong Stock Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement , make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement . INNOCARE 诺 诚 健 华 InnoCare Pharma Limited 諾 誠 健 華 醫藥 有限公司 ( Incorporated in the Cayman Islands with limited liability ) ( Stock code : 9969 ) INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2021 The board ( the " Board " ) of directors ( the “ Directors ” ) of InnoCare Pharma Limited ( the " Company " , and together with its subsidiaries , the “ Group ” ) is pleased to announce the unaudited consolidated results of the Group for the six months ended 30 June 2021 ( the " Reporting Period ” ) , together with comparative figures for the six months ended 30 June 2020. Unless otherwise defined herein , capitalised terms used in this announcement shall have the same meanings as those defined in the Prospectus . In this announcement , “ we ” , “ us ” “ our ” and “ InnoCare ” refer to the Company and where the context otherwise requires , the Group . Certain amount and percentage figure included in this announcement have been subject to rounding adjustments , or have been rounded to one or two decimal places . Any discrepancies in any table , chart or elsewhere totals and sums of amounts listed therein are due to rounding . BUSINESS HIGHLIGHTS During the six months ended 30 June 2021 , we continued advancing our drug pipeline and business operations , including the following milestones and achievements : Orelabrutinib Since China National Medical Products Administration ( “ NMPA ” ) had granted market approval on 25 December 2020 for the treatment of patients with relapsed and / or refractory chronic lymphocytic leukemia ( “ r / r CLL / SLL " ) and the treatment of patients with relapsed and / or refractory mantle cell lymphoma ( “ r / r MCL ” ) , our first prescription was issued within three weeks upon approval . During the Reporting Period , our newly established in - house sales team generated ( Orelabrutinib , BTK inhibitor ) revenue of RMB101 million . Orelabrutinib has been included in the Chinese Society of Clinical Oncology ( " CSCO " ) Diagnosis and Treatment Guidelines for Malignant Lymphoma 2021 ( the “ Guidelines " ) and is listed as a Class I recommended regimen for the treatment of r / r CLL / SLL and r / r MCL . 2021 National Reimbursement Drug List ( the “ NRDL ” ) revision process has been initiated and we are actively pursuing Orelabrutinib's inclusion in the NRDL . 1